NEW YORK (GenomeWeb News) – Foundation Medicine said today that it will use its genome sequencing and analysis services to identify genetic biomarkers and potential companion diagnostics for oncology drug candidates for Sanofi.
Foundation Medicine uses next-generation sequencing to analyze clinical specimens for molecular alterations in around 200 cancer-related genes. Its cancer genomic test is designed to provide clinical-grade analysis of tumor tissues, and test results are reported through a secure website that links pertinent genomic data to a knowledge base of relevant, publicly available data.
"Targeted cancer therapeutics routinely demonstrate improved clinical safety and efficacy when matched with the patients most likely to benefit, and we believe this alliance with Sanofi will help catalyze the development of their targeted candidates," Foundation Medicine President and CEO Michael Pellini said in a statement.
Financial terms of the agreement were not released.
The agreement with Sanofi marks the company's fifth collaboration with a pharmaceutical firm. It has signed similar deals with Johnson & Johnson Pharmaceutical Research and Development, Novartis, Celgene, and an undisclosed firm.